Trillium Therapeutics Inc. (TRIL)
| Market Cap | 938.69M |
| Revenue (ttm) | 116,078 |
| Net Income (ttm) | -109,020 |
| Shares Out | 103.14M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $9.11 |
| Previous Close | $9.26 |
| Change ($) | -0.15 |
| Change (%) | -1.62% |
| Day's Open | 9.06 |
| Day's Range | 8.95 - 9.42 |
| Day's Volume | 1,031,181 |
| 52-Week Range | 5.31 - 20.96 |
Trillium Therapeutics Inc (NASDAQ: TRIL) has provided a data update for TTI-622 and 621 programs in hematologic malignancies. As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective respo...
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
Their stocks have collapsed. But they could still be huge winners.
Though these stocks have dropped, upcoming news offers hope for them to rebound.
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
The cancer biotech soared in 2020, jumping up over 1,000% for the year. What will the stock do in 2021?
Trillium Therapeutics has two lead candidates that encourage immune cells known as “macrophages” to gobble up cancer cells by blocking a protein known as CD47. However, the CD47 inhibitor space is incre...
Buy these three biotech stocks before they take off.
When it comes to countering a key trick that cancer plays on the human immune system, this biotech has no equal.
The company's long-term plan is to challenge conventional cancer therapy.
This clinical-stage biotech stock could be a top buyout candidate in 2021.
Find out what these healthcare businesses can do to deliver big gains this year.
The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opport...
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
A decline in the stock price plus positive clinical data equals opportunity.
Trillium Therapeutics (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
The micro-cap has shot up an incredible 1,400% this year.
A new CEO and prioritization of research could have more big gains in store for the company
CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative ther...
Biotech investors had more than just vaccines to think about this year.
Investors are catching on to the opportunity for this innovative cancer therapy, and so is big pharma.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, t...
CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies fo...
Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest. The 2 major candidates, TTI-621 & 622 have shown monotherapy activity in a breadt...
Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board
Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative ther...
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies ...
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies ...
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapi...
Trillium (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Sorrento Therapeutics and Trillium Therapeutics could both be poised for another explosive move higher.
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapi...
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapi...
Shares of clinical stage immuno-oncology company Trillium Therapeutics Inc's (NASDAQ: TRIL) are trading higher on encouraging updated data from its ongoing lead cancer candidates TTI-622 and TTI-621 tha...
Trillium lands a noteworthy equity stake from pharma titan Pfizer.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapi...
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapi...
CAMBRIDGE, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapie...
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies...
Investors need to pay close attention to Trillium Therapeutics (TRIL) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the ...
Trillium Therapeutics (NASDAQ: TRIL) shares are trading higher on Friday, after the company provided an update on TTI-622 at ASCO.
About TRIL
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company ... [Read more...]
| Industry Biotechnology | Founded 2004 |
| Stock Exchange NASDAQ | Ticker Symbol TRIL |
Financial Performance
In 2020, TRIL's revenue was 148,000, an increase of 19.35% compared to the previous year's 124,000. Losses were -59.35 million, 55.8% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for TRIL stock is "Strong Buy." The 12-month stock price forecast is 11.02, which is an increase of 20.97% from the latest price.